Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down on Disappointing Earnings

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) gapped down prior to trading on Friday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $23.50, but opened at $21.54. Ultragenyx Pharmaceutical shares last traded at $21.0370, with a volume of 1,032,862 shares changing hands.

The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The firm had revenue of $207.00 million during the quarter, compared to the consensus estimate of $199.60 million. During the same quarter in the prior year, the business posted ($1.39) earnings per share. The firm’s quarterly revenue was up 25.5% on a year-over-year basis.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Strong revenue and product sales: Ultragenyx reported FY2025 total revenue of $673M with Crysvita® at $481M and Dojolvi® at $96M; Q4 revenue topped consensus, showing continued commercial traction. Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
• Positive Sentiment: Analyst stance remains constructive overall — coverage shows an average rating of “Moderate Buy,” which can underpin investor demand despite near-term headwinds. Ultragenyx Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Mixed quarter: EPS of ($1.29) missed estimates (~$1.20) even as revenue grew ~25% YoY — a mixed earnings picture that partially offsets the revenue beat. Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates
• Negative Sentiment: FY2026 revenue guidance of $730M–$760M missed Street expectations (~$785M), prompting investor concern about near-term growth and driving downward pressure on the stock. Ultragenyx shares fall as 2026 revenue guidance misses expectations
• Negative Sentiment: Program setback and workforce reduction: Ultragenyx laid off ~10% of staff after a Phase 3 brittle-bone (setrusumab) failure and amid FDA delays on gene therapy approvals — a material clinical and execution risk. Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
• Negative Sentiment: Rising litigation risk: Multiple law firms have filed or solicited investors for securities class actions covering Aug 3, 2023–Dec 26, 2025; potential legal exposure and distraction are additional headwinds. ROSEN Encourages Ultragenyx Investors to Secure Counsel

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on RARE shares. Truist Financial lowered their price objective on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Bank of America decreased their price target on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 3rd. Finally, Robert W. Baird cut their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $72.29.

Insider Activity

In related news, CFO Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the sale, the chief financial officer owned 95,146 shares of the company’s stock, valued at $3,461,411.48. The trade was a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 6,227 shares of company stock valued at $187,126 in the last three months. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently bought and sold shares of the business. Assetmark Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares during the last quarter. Huntington National Bank grew its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $39,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $55,000. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,169 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Down 10.5%

The stock has a market cap of $2.03 billion, a PE ratio of -3.54 and a beta of 0.16. The business has a 50 day moving average price of $27.23 and a 200 day moving average price of $29.78.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.